ALSUntangled no. 49: resveratrol

References

• http://www.alsuntangled.com/open.php. Accessed March 2, 2019. Archived by WebCite® Available at: http://www.webcitation.org/76Zpiz081
   Google Scholar
• Weiskirchen S, Weiskirchen R. Resveratrol: how much wine do you have to drink to stay healthy? Adv Nutr. 2016;7:706–18.
   PubMed Web of Science ®Google Scholar
• Park EJ, Pezzuto J. The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta. 2015;1852:1071–113.
   PubMed Web of Science ®Google Scholar
• Berman A, Motechin R, Wiesenfeld M, Holz M. The therapeutic potential of resveratrol: a review of clinical trials. Npj Precision Oncol. 2017;1:35.
   PubMed Web of Science ®Google Scholar
• Tellone E, Galtieri A, Russo A, Giardina B, Ficarra S. Resveratrol: a focus on several neurodegenerative diseases. Oxid Med Cell Longev. 2015;2015:392169.
   PubMed Web of Science ®Google Scholar
• Bisson J, McAlpine J, Friesen J, Chen SN, Graham J, Pauli G. Can invalid bioactives undermine natural product-based drug discovery? J Med Chem. 2016;59:1671–90.
   PubMed Web of Science ®Google Scholar
• Saqib U, Kelley TT, Panguluri SK, Liu D, Savai R, Baig MS. Polypharmacology or promiscuity? structural interactions of resveratrol with its bandwagon of targets. Front Pharmacol. 2018;9:1201.
   PubMed Web of Science ®Google Scholar
• The ALSUntangled Group. ALSUntangled 42: elysium health’s “basis.” Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:317–9.
   PubMed Web of Science ®Google Scholar
• Bonkowski M, Sinclair D. Slowing ageing by design: the rise of NAD + and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016;17:679–90.
   PubMed Web of Science ®Google Scholar
• Singh C, Chhabra G, Ndiaye M, Garcia-Peterson L, Mack N, Ahmad N. The role of sirtuins in antioxidant and redox signaling. Antioxid Redox Signal. 2018;28:643–61.
   PubMed Web of Science ®Google Scholar
• Salminen A, Kaarniranta K, Kauppinen A. Crosstalk between oxidative stress and SIRT1: impact on the aging process. Int J Mol Sci. 2013;14:3834–59.
   PubMed Web of Science ®Google Scholar
• Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal. 2013;25:1939–48.
   PubMed Web of Science ®Google Scholar
• Tomita T, Hamazaki J, Hirayama S, McBurney M, Yashiroda H, Murata S. Sirt1-deficiency causes defective protein quality control. Sci Rep. 2015;5:12613.
   PubMed Web of Science ®Google Scholar
• Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. Embo J. 2007;26:3169–79.
   PubMed Web of Science ®Google Scholar
• Herskovits AZ, Hunter TA, Maxwell N, Pereira K, Whittaker CA, Valdez G, et al. SIRT1 deacetylase in aging‐induced neuromuscular degeneration and amyotrophic lateral sclerosis. Aging Cell. 2018;17:e12839.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Ageta-Ishihara N, Nagatsu S, Takao K, Komine O, et al. SIRT1 overexpression ameliorates a mouse model of SOD1-linked amyotrophic lateral sclerosis via HSF1/HSP70i chaperone system. Mol Brain. 2014;7:62.
   PubMed Web of Science ®Google Scholar
• Mansur AP, Roggerio A, Goes MFS, Avakian SD, Leal DP, Maranhão RC, et al. Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: a randomized trial. Int J Cardiol. 2017;227:788–94.
   PubMed Web of Science ®Google Scholar
• Bo S, Togliatto G, Gambino R, Ponzo V, Lombardo G, et al. Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation. Acta Diabetol. 2018;55:331–40.
   PubMed Web of Science ®Google Scholar
• Goh K, Lee H, LAu D, Supaat W, Chan Y, Koh A. Effects of resveratrol in ratients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int J Sport Nutr Exercise Metab. 2014;24:2–13.
   PubMed Web of Science ®Google Scholar
• Timmers S, Konings E, Bilet L, Houtkooper R, van de Weijer T, et al. Calorie restriction-like effects of 30 days of resveratrol (resVida™) supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:5.
   PubMed Web of Science ®Google Scholar
• Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S-i, Schechtman KB, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose Tolerance. Cell Metab. 2012;16:658–64.
   PubMed Web of Science ®Google Scholar
• Asghari S, Asghari-Jafarabadi M, Somi MH, Ghavami SM, Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Am Coll Nutr. 2018;37:223–33.
   PubMed Web of Science ®Google Scholar
• Barber S, Higginbottom A, Mead R, Barber S, Shaw P. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic Biol Med. 2009;46:1127–38.
   PubMed Web of Science ®Google Scholar
• Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85:1383–91.
   PubMed Web of Science ®Google Scholar
• Moussa C, Hebron M, Huang X, Ahn J, Rissman R, Aisen PS, Turner RS. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation. 2017;14:1.
   PubMed Web of Science ®Google Scholar
• Mancuso R, del Valle J, Modol K, Martinez A, Granado-Serrano A, et al. Resveratrol improves motoneuron function and extends survival in SOD1G93A ALS mice. Neurotherapeutics. 2014;11:419–32.
   PubMed Web of Science ®Google Scholar
• Parakh S, Atkin J. Protein folding alterations in amyotrophic lateral sclerosis. Brain Res. 2016;1648:633–49.
   PubMed Web of Science ®Google Scholar
• Pare B, Lehmann M, Beaudin M, Nordstrom U, Saikali S, et al. Misfolded SOD1 pathology in sporadic amyotrophic lateral sclerosis. Sci Rep. 2018;8:14223.
   PubMed Web of Science ®Google Scholar
• Maier M, Welt T, Wirth F, Montrasio F, Preisig D, McAfoose J, et al. A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. Sci Transl Med. 2018;10:eaah3924.
   PubMed Web of Science ®Google Scholar
• Srinivasan E, Rajasekaran R. Quantum chemical and molecular mechanics studies on the assessment of interactions between resveratrol and mutant SOD1 (G93A) protein. J Comput Aided Mol Des. 2018;32:1347–61.
   PubMed Web of Science ®Google Scholar
• Malik R, Meng H, Wongkongkathep P, Corrales C, et al. The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. J Biol Chem. 2019;294:3501–3513
   PubMed Web of Science ®Google Scholar
• Brenner S. Blue-green algae or cyanobacteria in the intestinal micro-flora may produce neurotoxins such as Beta-N-Methylamino-L-Alanine (BMAA) which may be related to development of amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson-Dementia-Complex in humans and Equine Motor Neuron Disease in horses. Med Hypotheses. 2013;80:103.
   PubMed Web of Science ®Google Scholar
• Longstreth J, Meschke J, Davidson S, Smoot L, Smoot J, Koepsell T. Hypothesis: a motor neuron toxin produced by a clostridial species residing in gut causes ALS. Medical Hypotheses. 2005;64:1153–6.
   PubMed Web of Science ®Google Scholar
• Labarre A, Guitard E, Parker J. Variation of gut microbiome rescues paralysis and neurodegeneration profiles in C. elegans ALS models. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:245–6.
   PubMedGoogle Scholar
• Song L, Gao Y, Zhang X, Le W. Galactooligosaccharide improves the animal survival and alleviates motor neuron death in SOD1G93A mouse model of amyotrophic lateral sclerosis. Neuroscience. 2013;29:281–90.
   Google Scholar
• Zhang Y-g, Wu S, Yi J, Xia Y, Jin D, Zhou J, et al. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther. 2017;39:322–36.
   PubMed Web of Science ®Google Scholar
• Chaplin A, Carpene C, Mercader J. Resveratrol, metabolic syndrome, and gut microbiota. Nutrients. 2018;10:1651.
   PubMed Web of Science ®Google Scholar
• Brandt N, Kotowska D, Kristensen CM, Olesen J, Lützhøft DO, Halling JF, et al. The impact of exercise training and resveratrol supplementation on gut microbiota composition in high-fat diet fed mice. Physiol Rep. 2018;6:e13881.
   PubMed Web of Science ®Google Scholar
• Liao W, Yin X, Li Q, Zhang H, Liu Z, Zheng X, et al. Resveratrol-induced white adipose tissue browning in obese mice by remodeling fecal microbiota. Molecules. 2018;23:3356.
   Web of Science ®Google Scholar
• Most J, Penders J, Lucchesi M, Goossens G, Blaak E. Gut microbiota composition in relation to the metabolic response to 12-week combined polyphenol supplementation in overweight men and women. Eur J Clin Nutr. 2017;71:1040–5.
   PubMed Web of Science ®Google Scholar
• Korsholm A, Kjaer T, Ornstrup M, Pedersen S. Comprehensive metabolomic analysis in blood, urine, fat, and muscle in men with metabolic syndrome: a randomized, placebo-controlled clinical trial on the effects of resveratrol after four months’ treatment. Int J Mol Sci. 2017;18:554.
   Web of Science ®Google Scholar
• Wang J, Zhang Y, Tang L, Zhang N, Fan D. Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis. Neurosci Lett. 2011;503:250–5.
   PubMed Web of Science ®Google Scholar
• Stepanenko A, Dmitrenko V. Pitfalls of the MTT assay: direct and off-target effects of inhibitors can result in over/underestimation of cell viability. Gene. 2015;15:193–203.
   Google Scholar
• Laudati G, Mascolo L, Guida N, Sirabella R, Pizzorusso V, Bruzzaniti S, et al. Resveratrol treatment reduces the vulnerability of SH-SY5Y cells and cortical neurons overexpressing SOD1-G93A to thimerosal toxicity through SIRT1/DREAM/PDYN pathway. Neurotoxicology. 2018;71:6–15.
   PubMed Web of Science ®Google Scholar
• Yanez M, Galan L, Matias-Guiu J, Vela A, Guerrero A, Garcia A. CSF from amyotrophic lateral sclerosis patients produces glutamate independent death of rat motor brain cortical neurons: protection by resveratrol but not riluzole. Brain Res. 2011;1423:77–86.
   PubMed Web of Science ®Google Scholar
• Yanez M, Matias-Guiu J, Arranz-Tagarro J, Galan L, et al. The neuroprotection exerted by memantine, minocycline and lithium, against neurotoxicity of CSF from patients with amyotrophic lateral sclerosis, is antagonized by riluzole. Neurodegener Dis. 2014;13:171–9.
   PubMed Web of Science ®Google Scholar
• Rojas F, Cortes N, Abarzua S, Dyrda A, van Zundert B. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front Cell Neurosci. 2014;8:24.
   PubMed Web of Science ®Google Scholar
• Song L, Chen L, Zhang X, Li J, Le W. Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1G93A mouse model of amyotrophic lateral sclerosis. BioMed Res Int. 2014;2014:1.
   Google Scholar
• Han S, Choi JR, Soon Shin K, Kang SJ. Resveratrol upregulated heat shock proteins and extended the survival of G93A-SOD1 mice. Brain Res. 2012;1483:112–7.
   PubMed Web of Science ®Google Scholar
• Schiaffino L, Bonafede R, Scambi I, Parrella E, Pizzi M, Mariotti R. Acetylation state of RelA modulated by epigenetic drugs prolongs survival and induces a neuroprotective effect on ALS murine model. Sci Rep. 2018;8:12875.
   PubMed Web of Science ®Google Scholar
• Markert C, Kim E, Gifondorwa D, Childers M, Milligan C. A single-dose resveratrol treatment in a mouse model of amyotrophic lateral sclerosis. J Med Food. 2010;13:1081–5.
   PubMed Web of Science ®Google Scholar
• Mancuso R, del Valle J, Morell M, Pallas M, Osta R, Navarro X. Lack of synergistic effect of resveratrol and sigma-1 receptor agonist (PRE-084) in SOD1G93A ALS mice: overlapping effects or limited therapeutic opportunity? Orphanet J Rare Dis. 2014;9:78.
   PubMed Web of Science ®Google Scholar
• https://www.patientslikeme.com/conditions/als. Accessed: March 6, 2019.
   Google Scholar
• Harrison D, Mehta P, van Es M, Stommel E, Drory V. “ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities. Amyotroph Lateral Scler Frontotemporal Degenern. 2018. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• de la Rubia J, Drehmer E, Platero J, Benlloch M, Capilure-Llopis J, Villaron-Casales C, et al. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotroph Lateral Scler Frontotemporal Degener. 2019;1. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. How common are ALS plateaus and reversals? Neurology. 2016;86:808–12.
   PubMed Web of Science ®Google Scholar
• McCoy C. Understanding the intention-to-treat principle in randomized controlled trials. West J Emerg Med. 2017;18:1075–8.
   PubMed Web of Science ®Google Scholar
• Marelli C, Lamari F, Rainteau D, Lafourcade A, Banneau G, Humbert L, et al. Plasma oxysterols: biomarkers for diagnosis and treatment in spastic paraplegia type 5. Brain. 2018;141:72–84.
   PubMed Web of Science ®Google Scholar
• Blass J, Gibson G. Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans. J Alzheimers Dis. 2006;9:207–18.
   PubMed Web of Science ®Google Scholar
• Zhu C, Grossman H, Neugroschl J, Parker S, Burden A, et al. A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer’s disease: a pilot study. Alzheimers Demen. 2018;4:609–16.
   Google Scholar
• Cottart CH, Nivet-Antoine V, Beaudeux JL. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. 2014;58:7–21.
   PubMed Web of Science ®Google Scholar
• la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, et al. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010;49:449–54.
   PubMed Web of Science ®Google Scholar
• Popat R, Plesner T, Davies F, Cook G, et al. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol. 2013;160:709–22.
   PubMed Web of Science ®Google Scholar
• Couratier P, Corcia P, Lautrette G, Nicol M, Preux P, Marin B. Epidemiology of amyotrophic lateral sclerosis: a review of literature. Rev Neurol (Paris). 2016;172:37–45.
   PubMed Web of Science ®Google Scholar